Non small cell lung cancer metastatic cARBOplatin and gemcitabine (day 8 cARBOplatin): It is the consensus opinion of the respiratory reference committee that this protocol is not considered best practice for this patient population due to unacceptable toxicity, no clinical need and availability of superior alternatives.
Treatment Schedule Summary
||1 and 8
* if estimated GFR is greater than 125 mL/min (i.e. 5 AUC dose greater than 750 mg), obtaining direct measurement rather than an estimated renal function and/or dose capping is strongly recommended
Frequency: 21 days
Cycles: 4 unless otherwise indicated